Search Results - "Haura, Eric B."

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study by Park, Keunchil, Haura, Eric B, Leighl, Natasha B, Mitchell, Paul, Shu, Catherine A, Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K, Spira, Alexander I, Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E, Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M, Garrido, Pilar, Krebs, Matthew G, Reckamp, Karen L, Xie, John, Curtin, Joshua C, Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E, Cho, Byoung Chul

“…Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved…”
Get full text

Src kinases as therapeutic targets for cancer by Haura, Eric B, Kim, Lori C, Song, Lanxi

“…Src family kinases have been extensively studied and found to be central mediators in multiple signaling pathways that are important in oncogenesis…”
Get full text

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial by Creelan, Benjamin C., Wang, Chao, Teer, Jamie K., Toloza, Eric M., Yao, Jiqiang, Kim, Sungjune, Landin, Ana M., Mullinax, John E., Saller, James J., Saltos, Andreas N., Noyes, David R., Montoya, Leighann B., Curry, Wesley, Pilon-Thomas, Shari A., Chiappori, Alberto A., Tanvetyanon, Tawee, Kaye, Frederic J., Thompson, Zachary J., Yoder, Sean J., Fang, Bin, Koomen, John M., Sarnaik, Amod A., Chen, Dung-Tsa, Conejo-Garcia, Jose R., Haura, Eric B., Antonia, Scott J.

“…Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer by Gray, Jhanelle E, Saltos, Andreas, Tanvetyanon, Tawee, Haura, Eric B, Creelan, Ben, Antonia, Scott J, Shafique, Michael, Zheng, Hong, Dai, Wenjie, Saller, James J, Chen, Zhihua, Tchekmedyian, Nishan, Goas, Kristen, Thapa, Ram, Boyle, Theresa A, Chen, Dung-Tsa, Beg, Amer A

“…Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs)…”
Get full text

cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth by Chen, Zirong, Li, Jian-Liang, Lin, Shuibin, Cao, Chunxia, Gimbrone, Nicholas T, Yang, Rongqiang, Fu, Dongtao A, Carper, Miranda B, Haura, Eric B, Schabath, Matthew B, Lu, Jianrong, Amelio, Antonio L, Cress, W Douglas, Kaye, Frederic J, Wu, Lizi

“…The LKB1 tumor suppressor gene is frequently mutated and inactivated in non-small cell lung cancer (NSCLC). Loss of LKB1 promotes cancer progression and…”
Get full text

An immunoproteomic approach to characterize the CAR interactome and signalosome by Ramello, Maria C, Benzaïd, Ismahène, Kuenzi, Brent M, Lienlaf-Moreno, Maritza, Kandell, Wendy M, Santiago, Daniel N, Pabón-Saldaña, Mibel, Darville, Lancia, Fang, Bin, Rix, Uwe, Yoder, Sean, Berglund, Anders, Koomen, John M, Haura, Eric B, Abate-Daga, Daniel

“…Adoptive transfer of T cells that express a chimeric antigen receptor (CAR) is an approved immunotherapy that may be curative for some hematological cancers…”
Get more information

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling by Song, Lanxi, Rawal, Bhupendra, Nemeth, Jeffrey A, Haura, Eric B

“…Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention…”
Get full text

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer by Yoshida, Takeshi, Song, Lanxi, Bai, Yun, Kinose, Fumi, Li, Jiannong, Ohaegbulam, Kim C, Muñoz-Antonia, Teresita, Qu, Xiaotao, Eschrich, Steven, Uramoto, Hidetaka, Tanaka, Fumihiro, Nasarre, Patrick, Gemmill, Robert M, Roche, Joëlle, Drabkin, Harry A, Haura, Eric B

“…Epithelial-mesenchymal transition (EMT) is one mechanism of acquired resistance to inhibitors of the epidermal growth factor receptor-tyrosine kinases…”
Get full text

TGF-β—inducible microRNA-183 silences tumor-associated natural killer cells by Donatelli, Sarah S., Zhou, Jun-Min, Gilvary, Danielle L., Eksioglu, Erika A., Chen, Xianghong, Cress, W. Douglas, Haura, Eric B., Schabath, Matthew B., Coppola, Domenico, Wei, Sheng, Djeu, Julie Y.

“…Transforming growth factor β1 (TGF-β), enriched in the tumor microenvironment and broadly immunosuppressive, inhibits natural killer (NK) cell function by…”
Get full text

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling by Yin, Qing, Han, Tao, Fang, Bin, Zhang, Guolin, Zhang, Chao, Roberts, Evan R., Izumi, Victoria, Zheng, Mengmeng, Jiang, Shulong, Yin, Xiu, Kim, Minjung, Cai, Jianfeng, Haura, Eric B., Koomen, John M., Smalley, Keiran S. M., Wan, Lixin

“…BRAF plays an indispensable role in activating the MEK/ERK pathway to drive tumorigenesis. Receptor tyrosine kinase and RAS-mediated BRAF activation have been…”
Get full text

Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer by Dhawan, Andrew, Nichol, Daniel, Kinose, Fumi, Abazeed, Mohamed E., Marusyk, Andriy, Haura, Eric B., Scott, Jacob G.

“…Drug resistance remains an elusive problem in cancer therapy, particularly for novel targeted therapies. Much work is focused upon the development of an…”
Get full text

Proteogenomic landscape of squamous cell lung cancer by Stewart, Paul A., Welsh, Eric A., Slebos, Robbert J. C., Fang, Bin, Izumi, Victoria, Chambers, Matthew, Zhang, Guolin, Cen, Ling, Pettersson, Fredrik, Zhang, Yonghong, Chen, Zhihua, Cheng, Chia-Ho, Thapa, Ram, Thompson, Zachary, Fellows, Katherine M., Francis, Jewel M., Saller, James J., Mesa, Tania, Zhang, Chaomei, Yoder, Sean, DeNicola, Gina M., Beg, Amer A., Boyle, Theresa A., Teer, Jamie K., Ann Chen, Yian, Koomen, John M., Eschrich, Steven A., Haura, Eric B.

“…How genomic and transcriptomic alterations affect the functional proteome in lung cancer is not fully understood. Here, we integrate DNA copy number, somatic…”
Get full text

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer by Superti-Furga, Giulio, Koomen, John, Haura, Eric B, Li, Jiannong, Rix, Uwe, Fang, Bin, Bai, Yun, Edwards, Arthur, Colinge, Jacques, Bennett, Keiryn L, Gao, Jingchun, Song, Lanxi, Eschrich, Steven

“…Determining relevant targets of promiscuous kinase inhibitors has proven difficult. A combination of two mass spectrometry–based proteomic approaches, RNAi…”
Get full text

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer by Song, Lanxi, Smith, Matthew A, Doshi, Parul, Sasser, Kate, Fulp, William, Altiok, Soner, Haura, Eric B

“…Interleukin-6 (IL-6) can activate downstream signaling pathways in lung cancer cells, such as the STAT3 pathway, and is reported to be produced by tumor cells…”
Get more information

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer by Yoshida, Takeshi, Zhang, Guolin, Haura, Eric B.

“…Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Platinum-based doublets remain the current standard therapy for advanced…”
Get full text

Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy by Kim, Eunjung, Kim, Jae-Young, Smith, Matthew A, Haura, Eric B, Anderson, Alexander R A

“…During the last decade, our understanding of cancer cell signaling networks has significantly improved, leading to the development of various targeted…”
Get full text

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells by Remsing Rix, Lily L, Sumi, Natalia J, Hu, Qianqian, Desai, Bina, Bryant, Annamarie T, Li, Xueli, Welsh, Eric A, Fang, Bin, Kinose, Fumi, Kuenzi, Brent M, Chen, Y Ann, Antonia, Scott J, Lovly, Christine M, Koomen, John M, Haura, Eric B, Marusyk, Andriy, Rix, Uwe

“…Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in…”
Get more information

Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER by Putty Reddy, Sudhir, Alontaga, Aileen Y., Welsh, Eric A., Haura, Eric B., Boyle, Theresa A., Eschrich, Steven A., Koomen, John M.

“…Liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) has widespread clinical use for detection of inborn errors of metabolism,…”
Get full text

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer by Kim, Jae-Young, Welsh, Eric A, Fang, Bin, Bai, Yun, Kinose, Fumi, Eschrich, Steven A, Koomen, John M, Haura, Eric B

“…Pathway inhibition of the RAS-driven MAPK pathway using small-molecule kinase inhibitors has been a key focus for treating cancers driven by oncogenic RAS, yet…”
Get full text